Logo

Galapagos Raises $27.1M in Share Placement

Oct 17, 2009

NEW YORK (GenomeWeb News) – Galapagos, the Belgian drug development and drug screening services firm, has raised €18.2 million ($27.1 million) through the placement of 2,125,925 new ordinary shares at a price of €8.55 per share.

The shares are being placed with unnamed international institutional investors. Delivery of the shares is expected to take place on Oct. 21.

Galapagos plans to use the funds to support clinical development of drug candidates, including a phase II study of a rheumatoid arthritis drug.

The firm did not say whether any of the proceeds will be used by its BioFocus DPI division, which conducts drug validation and screening services.

Filed under

financing
Galapagos
Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.